Stock Scorecard

Stock Summary for Silence Therapeutics Plc (SLN) - $6.25 as of 12/3/2025 12:21:53 PM EST

Total Score

11 out of 30

Safety Score

26 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for SLN

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for SLN

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for SLN

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for SLN

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for SLN (26 out of 100)

Stock Price Rating (Max of 10) 4
Historical Stock Price Rating (Max of 10) 7
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 2
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 3
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 5
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for SLN

Silence Therapeutics (OTCMKTS:SLNCF) Trading 6.7% Higher – Should You Buy? 10/17/2025 6:00:00 AM
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives $32.60 Average Price Target from Analysts - Defense World 10/13/2025 5:39:00 AM
Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting 12/31/2024 11:59:00 PM
Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting 12/9/2024 12:00:00 AM
SLNCF Stock Price and Chart — OTC:SLNCF 12/31/2023 11:59:00 PM
SLN124, a GalNAc conjugated 19‐mer siRNA targeting tmprss6, reduces plasma iron and increases hepcidin levels of healthy volunteers 7/27/2023 12:00:00 AM
RNA Based Therapeutic Market Trend 2023: Anticipated Growth to Reach $25.12 Billion by 2030 | 17.6% 6/23/2023 12:00:00 AM
Silence Therapeutics Appoints J.P. Gabriel as Chief Technical Operations Officer 2/6/2023 12:00:00 AM
Polycythemia Vera mRNA Therapy Receives FDA Fast Track Designation 9/8/2022 12:00:00 AM
Cleveland Clinic-Led Trial Finds That Experimental ‘Gene Silencing’ Therapy Reduces Lipoprotein(a), an Important Risk Factor of Heart Disease, By Up To 98% 4/3/2022 12:00:00 AM

Financial Details for SLN

Company Overview
Ticker SLN
Company Name Silence Therapeutics Plc
Country USA
Description Silence Therapeutics PLC, headquartered in London, is a pioneering biotechnology firm focused on developing revolutionary RNA therapies to meet critical medical needs across hematology, cardiovascular diseases, and rare metabolic disorders. Utilizing its proprietary RNA interference (RNAi) technology platform, the company is advancing a diverse pipeline of innovative therapeutics aimed at precisely targeting disease mechanisms. Silence Therapeutics is dedicated to redefining treatment paradigms in the biopharmaceutical sector and improving patient outcomes through its cutting-edge RNA-based solutions.
Sector Name HEALTHCARE
Industry Name BIOTECHNOLOGY
Most Recent Quarter 9/30/2025
Next Earnings Date N/A

Stock Price History
Last Day Price 6.25
Price 4 Years Ago 23.89
Last Day Price Updated 12/3/2025 12:21:53 PM EST
Last Day Volume 484,880
Average Daily Volume 221,344
52-Week High 8.88
52-Week Low 1.97
Last Price to 52 Week Low 217.26%

Valuation Measures
Trailing PE N/A
Industry PE 43.11
Sector PE 88.06
5-Year Average PE 16.66
Free Cash Flow Ratio 3.59
Industry Free Cash Flow Ratio 13.81
Sector Free Cash Flow Ratio 28.78
Current Ratio Most Recent Quarter 7.69
Total Cash Per Share 1.74
Book Value Per Share Most Recent Quarter 1.57
Price to Book Ratio 4.30
Industry Price to Book Ratio 33.69
Sector Price to Book Ratio 33.12
Price to Sales Ratio Twelve Trailing Months 12.05
Industry Price to Sales Ratio Twelve Trailing Months 31.75
Sector Price to Sales Ratio Twelve Trailing Months 15.97
Analyst Buy Ratings 3
Analyst Strong Buy Ratings 2

Share Statistics
Total Shares Outstanding 47,233,900
Market Capitalization 295,211,875
Institutional Ownership 42.00%

Dividends
Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement
Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -4.72%
Reported EPS 12 Trailing Months -1.35
Reported EPS Past Year -1.30
Reported EPS Prior Year -1.04
Net Income Twelve Trailing Months -62,667,815
Net Income Past Year -45,309,000
Net Income Prior Year -43,267,000
Quarterly Revenue Growth YOY -89.40%
5-Year Revenue Growth 181.67%
Operating Margin Twelve Trailing Months -14,881.00%

Balance Sheet
Total Cash Most Recent Quarter 82,031,000
Total Cash Past Year 121,330,000
Total Cash Prior Year 68,789,000
Net Cash Position Most Recent Quarter 82,031,000
Net Cash Position Past Year 121,330,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 134,023,000
Total Stockholder Equity Prior Year 21,993,000
Total Stockholder Equity Most Recent Quarter 74,063,000

Free Cash Flow
Free Cash Flow Twelve Trailing Months -69,959,064
Free Cash Flow Per Share Twelve Trailing Months -1.48
Free Cash Flow Past Year -67,851,000
Free Cash Flow Prior Year -39,395,000

Options
Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis
Yahoo Finance Chart Yahoo Finance Chart
MACD -0.01
MACD Signal 0.09
20-Day Bollinger Lower Band 4.21
20-Day Bollinger Middle Band 5.87
20-Day Bollinger Upper Band 7.53
Beta 1.34
RSI 45.33
50-Day SMA 5.31
150-Day SMA 11.14
200-Day SMA 11.70

System
Modified 12/2/2025 8:58:20 AM EST